Council of Scientific and Industrial Research

Arun Kumar Trivedi

Brijesh Kumar

Abhishek Kumar Singh

Rakesh Maurya

Sabyasachi Sanyal

Srikanta Kumar Rath

Naibedya Chattopadhyay

Atul Kumar

Prabhat Ranjan Mishra

Anil Kumar Tripathi

Anagha Gurjar

Naresh Mittapelly

Riyazuddin Mohammed

Kamal Ram Arya

Nidhi Singh

Sudhir Kumar

Jiaur Rahaman Gayen

Jitendra Kumar Kanuajiya

Kunal Sharan

Preety Dixit

Ramakrishna Eppalapally

Padam Kumar

Subhashis Pal

Jawahar Lal

Naibedya Chattopadhayay

Dipak Datta

Tahseen Akhtar

Shailendra Kumar Dhar Dwivedi

Sapana

Manisha Yadav

Bandana Chakravarti

Maurya Rakesh

Jay Sharan Mishra

Pooja Pal

Savita Lochab

Smrati Bhadauria

Rashmi Kumari

Parvez Mohammad Khan

Kainat Khan

Devendra Pratap Mishra

Sharad Sharma

Ram Arya Kamal

The present invention relates to a bioactive extract, fraction ofand formulation thereof for bone regeneration and treatment of glucocorticoid induced musculo-skeletal diseases and associated electrolyte imbalances.

Bioactive extract, fraction ofand formulation thereof for bone regeneration

The present invention relates to substituted aryl naphthyl methanone oximes of general formula (I), their process for preparation and their derivatives, salts, pharmaceutical composition thereof and their use in treatment of chronic myelogenous leukemia, acute myelogenous leukemia, lymphoma, multiple myeloma, solid tumor forming cell-lines including such as breast cancer, endometrial cancer colon cancer, prostate cancer and killing of drug resistant cancer stem cells, as subject in need thereof. 

Aryl naphthyl methanone oxime(s) and process for preparation thereof

The present invention provides the compound Ormeloxifene [3, 4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like C/EBP&#x3b1; and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (GCSFr). Differentiated cells having neutrophil like morphology were observed when treated with 1.0 uM to 7.5 uM ORM which clearly indicates that ORM can induce differentiation in myeloid leukemia cells. At higher doses (5 uM to 7.5 uM) there is early onset of myeloid differentiation (24 to 48 h) with reduced no. of cells which is likely due to apoptotic effects of ORM at higher does. In contrary, lower doses (1 uM) induce differentiation after longer duration (6-15 days) with quite reduced apoptotic effect.

Anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells

Growing community of inventors

Lucknow, India

Arun Kumar Trivedi